Silence Therapeutics (NASDAQ:SLN) Earns “Buy” Rating from Chardan Capital

Silence Therapeutics (NASDAQ:SLN)‘s stock had its “buy” rating reaffirmed by analysts at Chardan Capital in a note issued to investors on Friday,Benzinga reports. They currently have a $35.00 target price on the stock.

A number of other research firms have also recently commented on SLN. Wall Street Zen cut shares of Silence Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, July 12th. Morgan Stanley lowered their price target on shares of Silence Therapeutics from $45.00 to $25.00 and set an “overweight” rating on the stock in a report on Friday, May 9th. HC Wainwright reaffirmed a “buy” rating and issued a $75.00 price target on shares of Silence Therapeutics in a report on Friday, June 13th. Finally, The Goldman Sachs Group lowered their price target on shares of Silence Therapeutics from $4.00 to $3.00 and set a “sell” rating on the stock in a report on Friday, May 9th. Two research analysts have rated the stock with a sell rating and six have given a buy rating to the company. According to data from MarketBeat.com, Silence Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $33.83.

Silence Therapeutics Stock Performance

Shares of NASDAQ SLN opened at $5.04 on Friday. Silence Therapeutics has a twelve month low of $1.97 and a twelve month high of $20.48. The stock’s 50 day moving average price is $5.81 and its 200-day moving average price is $4.70.

Silence Therapeutics (NASDAQ:SLN) last announced its earnings results on Thursday, August 7th. The company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.27). Silence Therapeutics had a negative return on equity of 63.50% and a negative net margin of 294.20%. The business had revenue of $0.22 million during the quarter, compared to analysts’ expectations of $8.50 million. As a group, research analysts anticipate that Silence Therapeutics will post -1.77 EPS for the current fiscal year.

Institutional Investors Weigh In On Silence Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. GAMMA Investing LLC raised its holdings in Silence Therapeutics by 134.1% during the 2nd quarter. GAMMA Investing LLC now owns 8,333 shares of the company’s stock valued at $48,000 after acquiring an additional 4,773 shares during the period. Walleye Capital LLC raised its holdings in Silence Therapeutics by 274.1% during the 1st quarter. Walleye Capital LLC now owns 136,150 shares of the company’s stock valued at $384,000 after acquiring an additional 99,753 shares during the period. Jump Financial LLC bought a new stake in Silence Therapeutics during the 1st quarter valued at $74,000. Woodline Partners LP raised its holdings in Silence Therapeutics by 22.6% during the 4th quarter. Woodline Partners LP now owns 498,732 shares of the company’s stock valued at $3,431,000 after acquiring an additional 91,829 shares during the period. Finally, Two Sigma Advisers LP grew its position in shares of Silence Therapeutics by 18.6% during the 4th quarter. Two Sigma Advisers LP now owns 98,800 shares of the company’s stock valued at $680,000 after purchasing an additional 15,500 shares in the last quarter. Institutional investors own 98.73% of the company’s stock.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.